Vilon (KE Dipeptide): Complete Research Profile — Khavinson Thymus & Immune Bioregulator (2026)

# Vilon (KE Dipeptide): Complete Research Profile — Khavinson Thymus & Immune Bioregulator (2026)

Vilon is the smallest of the Khavinson bioregulatory peptides — a dipeptide consisting of just two amino acids: Lys-Glu (KE). Despite its extreme brevity (molecular weight ~275 Da), it has been studied as the minimal active sequence derived from thymalin, the natural thymic polypeptide extract developed in the 1970s Khavinson research program, and is proposed to carry thymic and immune-regulatory biological activity in a single molecular unit.

This research profile covers Vilon's molecular characteristics, its relationship to the thymic immune system, the proposed immunomodulatory mechanism, published research findings from the Khavinson group, and how it compares to other thymic and immune peptides in the research space.

> Disclaimer: This article is for educational and research purposes only. Vilon is not approved by the FDA or equivalent agencies for therapeutic use. Nothing herein constitutes medical advice.

---

What Is Vilon?

Vilon is a synthetic dipeptide — the simplest possible peptide: just two amino acids joined by a single peptide bond. Its sequence is Lys-Glu (Lysine-Glutamic acid), abbreviated in one-letter code as KE. The chemical structure is H-Lys-Glu-OH in its standard free-form.

The peptide occupies a unique position within the Khavinson bioregulatory system as the most structurally minimal member: even shorter than the tripeptides (Pinealon/EDR, Vesugen/KED, Cartalax/AED) and tetrapeptides (Testagen/KEDG, Livagen/KEDA, Prostamax/KEDP, Cardiogen/AEDR) that make up most of the catalog.

Vilon was identified as the minimal biologically active sequence within thymalin — the thymic polypeptide complex that had demonstrated immunomodulatory activity in Soviet clinical and preclinical research since the 1970s. By systematically shortening the thymalin polypeptide mixture and testing fragments, Khavinson's group identified the Lys-Glu dipeptide as retaining key thymic activity at its irreducible minimum.

The name "Vilon" is a proprietary designation; the peptide may also be found in literature as KE dipeptide, H-Lys-Glu-OH, or simply the lysyl-glutamate dipeptide.

Key Characteristics at a Glance

---

The Thymus: What Vilon Is Designed to Target

Thymic Biology and Immune Development

The thymus is a specialized primary lymphoid organ located in the upper chest (mediastinum), and it serves as the training ground for T lymphocytes — the adaptive immune cells responsible for cell-mediated immunity. The thymus is essential for:

• •T cell development: Hematopoietic precursors from bone marrow migrate to the thymus, where they undergo selection and maturation into functional T cells
• •Central tolerance: Self-reactive T cells are eliminated in the thymus through negative selection, preventing autoimmunity
• •T cell repertoire diversity: The thymus enables the generation of a diverse T cell receptor repertoire capable of recognizing virtually any pathogen

The thymic microenvironment — maintained by thymic epithelial cells, dendritic cells, and macrophages — provides the signals (cytokines, cell contact, extracellular matrix proteins) that guide T cell development through defined stages:

• •DN (double negative) → DP (double positive) → SP (single positive, either CD4+ or CD8+)
• •Positive selection for MHC-restricted recognition
• •Negative selection for self-tolerance

Thymic Involution: The Immunological Clock of Aging

One of the most consistent phenomena in aging biology is thymic involution — the progressive atrophy of the thymus with age. This process begins surprisingly early:

• •Thymic volume and activity peak around puberty (ages 10–15)
• •Progressive replacement of active thymic tissue with adipose tissue begins in adolescence
• •By age 40, thymic output of new T cells (recent thymic emigrants, RTEs) is reduced by ~50%
• •By age 60–70, only ~5–10% of original thymic function remains

The consequences of thymic involution are profound:

• •Reduced T cell diversity: The peripheral T cell pool is replenished less frequently with new cells bearing novel receptors
• •Accumulation of terminally differentiated T cells: The immune repertoire becomes progressively dominated by memory and effector cells with narrowed specificity
• •Impaired responses to new pathogens and vaccines: Both infection defense and vaccine efficacy decline with thymic function
• •Immune senescence: The overall functional impairment of the adaptive immune system with age

This age-related thymic decline is the primary context in which Vilon research is conducted — investigating whether a thymic-targeted bioregulatory peptide can support or restore thymic and immune cell function in aging subjects.

---

Proposed Mechanism of Action

Thymalin and the Minimal Thymic Signal

Vilon's development as a defined molecule arose from thymalin — a polypeptide extract of calf thymus glands that showed immunomodulatory properties in early Khavinson research. Thymalin is a complex mixture of peptides; the systematic identification of its minimal active sequence led to the Lys-Glu dipeptide (Vilon).

The biological rationale is that thymic tissue — like all organs in the Khavinson model — produces short peptide bioregulators that carry tissue-specific gene regulatory information. The thymus produces peptide signals (including natural thymic hormones thymosin α₁, thymopoietin, thymostimulin, and others) that regulate T cell development; Vilon represents the Khavinson interpretation of this signaling system at its simplest level.

Proliferation and Apoptosis Balance

The most documented cellular effect of Vilon is its ability to modulate the balance between cellular proliferation and apoptosis in immune and epithelial cells.

Preclinical studies demonstrate that Vilon:

• •Stimulates proliferative activity of thymocytes — promotes the expansion of thymic precursor cells
• •Modulates apoptosis — can either support cell survival (reducing excessive apoptosis in aging tissue) or promote normal programmed cell death in activated immune cells, depending on cellular context
• •Supports lymphocyte function — T cell and B cell activity regulation consistent with thymic signaling

This dual regulation of proliferation and apoptosis is consistent with the broader Khavinson epigenetic framework, where tissue-specific peptides restore appropriate gene expression programs in aging cells — including both survival signals and normal cell cycle regulation.

Chromatin and Gene Expression Effects

Like other Khavinson peptides, Vilon is proposed to function through nuclear entry and DNA/chromatin interaction:

• •As a KE dipeptide, Vilon is extraordinarily small — easily permeable across both cell membranes and nuclear pores
• •Interaction with DNA regulatory sequences in thymic gene promoters would modulate expression of thymic development factors, cytokines, and cell surface markers
• •Chromatin accessibility studies (analogous to those conducted for Livagen) have been proposed for Vilon but are less extensively published

Secondary Tissue Effects

Beyond immune tissue, published research has examined Vilon effects in:

• •Retinal cells: Some research suggests effects on proliferative activity in retinal epithelial cells
• •Neurons: Neural tissue studies have examined whether KE dipeptide affects neuronal gene expression programs
• •Wound healing models: Vilon has been studied for effects on tissue repair and regeneration, consistent with the immune component of wound healing

---

Published Research Findings

Immunomodulatory Studies

Vilon has been studied in preclinical models of immune function, with research primarily from the Khavinson group and St. Petersburg Institute:

Thymocyte Proliferation Studies:

• •Cell culture experiments in murine thymocytes demonstrate Vilon-stimulated proliferative activity compared to untreated controls
• •Effects are dose-dependent with an optimal concentration range
• •Aged thymocyte cultures show greater responses than young cultures, consistent with restoration of age-related deficits

Immune Cell Apoptosis Regulation:

• •Vilon treatment modulates apoptotic markers in immune cell cultures
• •Appears to reduce excessive apoptosis in aged immune cells while maintaining appropriate apoptotic clearance of activated cells
• •p53 and Bcl-2 family protein involvement proposed

Cytokine Profile Effects:

• •Some published work documents changes in cytokine secretion profiles following Vilon treatment in immune cell cultures
• •Shifts toward more balanced pro-inflammatory/anti-inflammatory profiles

Connection to Thymalin Clinical Data

While Vilon itself has a limited clinical evidence base, it derives conceptually from thymalin — which has the most extensive clinical record of any Khavinson preparation:

• •Thymalin was studied in the landmark St. Petersburg geriatric trials showing 2.0–2.1 fold mortality reduction in elderly patients
• •As the proposed minimal active sequence of thymalin, Vilon's potential significance is informed by this clinical work — though it cannot be assumed that the dipeptide fully recapitulates the complex polypeptide activity
• •Thymalin received pharmaceutical approval in Russia and continues to be used clinically

Evidence Limitations

• •Published Vilon studies are primarily in vitro (cell culture) and involve rodent models
• •No randomized controlled trials using defined Vilon (KE dipeptide) have been published
• •Research is concentrated in the Khavinson group; independent replication is limited
• •Precise mechanism (DNA binding sequences, gene expression changes) is not fully characterized

---

Comparison With Other Thymic and Immune Peptides

Within the Khavinson Family

Versus Other Thymic Research Peptides

Thymosin α₁ (Tα₁):

• •A 28-amino acid thymic hormone with well-characterized immunomodulatory mechanisms
• •Acts through toll-like receptors and dendritic cell activation
• •More mechanistically characterized than Vilon; used clinically in some countries for viral infections and cancer immunotherapy
• •Much larger and receptor-mediated vs. Vilon's proposed nuclear entry mechanism

Thymopoietin (TP5, Thymopentin):

• •5-amino acid thymic peptide (Arg-Lys-Asp-Val-Tyr) with documented T cell maturation effects
• •One of the original short thymic peptides characterized before Khavinson's work
• •Receptor-mediated (CD90 signaling) vs. Vilon's proposed epigenetic mechanism

Thymulin (FTS):

• •Nonapeptide thymic hormone requiring zinc for activity
• •Acts on T cell maturation markers (Thy-1, TdT)
• •Well-characterized mechanism through zinc-dependent conformational change

Vilon stands apart from these established thymic peptides primarily in its extreme simplicity (2 amino acids vs. 5–28) and its proposed mechanism (epigenetic vs. receptor-mediated).

---

Research Considerations

The KE Sequence Across Biology

The Lys-Glu (KE) dipeptide is notable because the same two-amino acid combination appears in multiple biological contexts:

• •As a C-terminal or internal motif in various larger peptides and proteins
• •Within other Khavinson peptides: Vesugen (KED), Testagen (KEDG), Livagen (KEDA), and Prostamax (KEDP) all contain the KE core plus additional residues
• •This has led some researchers to propose that KE represents a minimal "anchor" sequence with broad epigenetic activity, with the additional residues providing tissue-targeting specificity

This relationship between Vilon (KE) and the larger KE-family peptides is one of the most interesting structural questions in the Khavinson bioregulator system.

Research Grade Vilon

For research use:

• •Standard purity: ≥98% by HPLC
• •Verification: MS confirmation of KE dipeptide molecular weight (~275.30 Da)
• •Storage: Lyophilized form at -20°C; stable for extended periods; reconstituted solutions should be aliquoted and stored frozen

---

Frequently Asked Questions

What is Vilon derived from?

Vilon was identified as the minimal biologically active sequence within thymalin — a polypeptide extract of calf thymus tissue. It represents the shortest possible sequence that retains the proposed thymic regulatory activity.

Is Vilon the same as Thymalin?

No. Thymalin is a complex polypeptide extract; Vilon (KE) is a defined synthetic dipeptide proposed to be the minimal active sequence within that extract. They share target tissue (thymus/immune cells) but differ fundamentally in complexity and characterization.

How does Vilon relate to other KE-containing peptides?

Vesugen (KED), Testagen (KEDG), Livagen (KEDA), and Prostamax (KEDP) all contain the KE dipeptide within their longer sequences. This has led to the hypothesis that KE is a core epigenetic motif, with the additional residues directing tissue specificity.

Has Vilon been studied for specific immune conditions?

Published research focuses on general immunomodulation, thymocyte proliferation, and aging-related immune decline. Specific immune disease models (autoimmune conditions, specific viral infections) are not extensively represented in the available literature.

---

Summary

Vilon (KE, Lys-Glu dipeptide) is the minimal thymic bioregulatory peptide in the Khavinson system — two amino acids carrying the proposed tissue-specific epigenetic signal for immune and thymic tissue. As the derived minimal sequence from thymalin, it connects to the most clinically studied arm of the Khavinson program.

Its proposed mechanisms — stimulation of thymocyte proliferation, modulation of immune cell apoptosis balance, and epigenetic restoration of thymic gene expression programs — are scientifically coherent in the context of the well-documented age-related thymic involution that drives immune senescence.

The evidence base consists primarily of preclinical in vitro data from the Khavinson group; independent replication and human clinical trials using defined Vilon are absent from the current literature.

---

Further Reading:

• •Prostamax (KEDP Tetrapeptide): Complete Research Profile — Khavinson Prostate Bioregulator (2026)
• •Vesugen (KED Tripeptide): Complete Research Profile — Khavinson Vascular Endothelium Bioregulator (2026)
• •Cardiogen: Complete Research Profile — Khavinson Cardiac Bioregulatory Tetrapeptide (AEDR) for Heart Tissue Research (2026)
• •Testagen (KEDG Tetrapeptide): Complete Research Profile — Khavinson Testicular & Reproductive Bioregulator (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder

---

Related Articles:

• •Khavinson Bioregulatory Peptides: Complete Guide
• •Livagen (KEDA): Liver & Chromatin Bioregulator
• •Testagen (KEDG): Testicular Bioregulator

This article is for educational and research purposes only. Vilon is not an approved therapeutic agent. Nothing herein constitutes medical advice.